Pfizer says Phase 3 trials show LITFULO improves repigmentation in nonsegmental vitiligo patients at Week 52

Bitget2026/10/02 15:15

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Pfizer presented Phase 3 results showing LITFULO improved facial repigmentation and overall skin repigmentation in nonsegmental vitiligo versus placebo.
Benefits built over time, with continued improvement from mid-study through one year, supporting a systemic treatment approach for the disease.
Safety matched the drug’s established profile in alopecia areata, with no new safety signals reported in the vitiligo program.
Pfizer plans regulatory submissions to the FDA and EMA, aiming to expand LITFULO beyond its current alopecia areata indication.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pfizer Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202610021115BIZWIRE_USPR_____20261002_BW026421) on October 02, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Pfizer says Phase 3 trials show LITFULO improves repigmentation in nonsegmental vitiligo patients at Week 52

You may also like

Crypto prices